Ajanta Pharma is currently trading at Rs. 1204.95, up by 4.00 points or 0.33% from its previous closing of Rs. 1200.95 on the BSE.
The scrip opened at Rs. 1211.10 and has touched a high and low of Rs. 1215.65 and Rs. 1201.55 respectively. So far 1,465 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2150.00 on 28-Oct-2016 and a 52 week low of Rs. 1106.00 on 22-Aug-2017.
Last one week high and low of the scrip stood at Rs. 1249.00 and Rs. 1183.50 respectively. The current market cap of the company is Rs. 10,604.00 crore.
The promoters holding in the company stood at 73.78%, while Institutions and Non-Institutions held 13.81% and 12.41% respectively.
Ajanta Pharma has received final approval from US Food and Drug Administration (USFDA) for Entacapone Tablets. It is a bioequivalent generic version of Comtan Tablets. The company will be launching the product shortly in 200mg strength tablets.
Entacapone Tablets is part of an ever growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 35 Abbreviated New Drug Application (ANDA) of which it has final approvals for 20 ANDAs; tentative approvals for 2 ANDA; and 13 ANDAs are under review with USFDA.
Ajanta Pharma is a specialty pharmaceutical formulation company with global headquarters in Mumbai, India. Over 6,500 employees are engaged in developing, manufacturing and marketing of quality finished dosages across 30+ countries.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: